IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study.
The acute antidyskinetic effects of IV amantadine in HD were evaluated. A 2-hour IV infusion of amantadine or placebo was administered to nine patients with HD on two different days in a double-blind, randomized crossover fashion. All patients subsequently received oral amantadine unblinded for a 1-year period. A reduction of dyskinesia scores was reported during both IV and oral amantadine treatment (p < 0.05). No significant changes were observed in neuropsychological tests or psychiatric rating scales.
Lucetti
C
C
Department of Neuroscience, University of Pisa, Pisa, Italy.
Del Dotto
P
P
Gambaccini
G
G
Dell' Agnello
G
G
Bernardini
S
S
Rossi
G
G
Murri
L
L
Bonuccelli
U
U
D000284:Administration, Oral; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018691:Excitatory Amino Acid Antagonists; D018698:Glutamic Acid; D000547:Amantadine